WillItSurvive
Medical technology and health companies · Australia

Pro Medicus

promedicus.com.au ↗

Australian maker of Visage 7, cloud imaging software radiologists use to read scans.

Hard to displace
Assessed 30 July 2026 · Evidence as of 30 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 30 July 2026 · Checkable from mid-August 2026 · Every call on the record Checkpoint: FY2026 full-year results announcement
The call

Pro Medicus keeps renewing at higher fees and signing new hospital archive deals while AI vendors sell add-on tools inside its platform.

Pro Medicus sells Visage 7, software that hospitals use to store, view, and manage medical images (X-rays, CT scans, MRIs). It is deeply woven into hospital routines and systems, which makes it sticky: hospitals almost never cancel, and even during the recent AI panic, a major hospital system renewed at higher prices. The big rivals like GE HealthCare and Siemens sell similar products, and AI companies like Aidoc are growing fast with AI-powered analysis tools, but they plug into platforms like Visage rather than replace it entirely. The real test is whether AI-native companies start building their own full imaging platforms with storage and viewing tools, not just AI analysis layers; watch how many new hospitals pick Visage in the next few contract cycles and whether renewal prices hold steady or slide.

Why
01
AI pressure: Aidoc. Aidoc and Sirona sell AI tools that plug into Visage today, but both want to become the main reading platform, not just a feature. Could AI do the core job? Unlikely.
02
Bigger players: GE HealthCare, Siemens Healthineers. GE and Siemens sell their own PACS and cleared AI devices, yet Pro Medicus keeps winning new hospitals and renewing against them. Could a giant copy it? No, they are blocked.
03
What protects it. Hospitals run years of imaging history through Visage; ripping it out risks patient data and radiologist workflow, so they renew instead.
What would change this call
Aidoc or Sirona ships a full archive/viewer layer replacing (not plugging into) a Visage 7 site. Would show AI-native rivals moving from feature add-ons to true platform competitors.
A major US academic hospital (Trinity, Duke, Sutter, Allegheny) does not renew or renews at lower fees. Would show Pro Medicus's pricing power and lock-in eroding.
Pro Medicus new contract win value (FY2026 disclosed figure vs A$520M FY2025) at next results. Would show whether new-logo momentum against rivals is slowing.
Key numbers
  • FY2025 revenue A$213.0M, up 31.9% (2025-06-30)
  • FY2025 net profit A$115.2M, up 39.2% (2025-06-30)
  • A$520M in new contract wins, FY2025 (2025-06-30)
Named risks
  • Valuation gap: Morningstar fair value A$57 vs market price ~A$150-160 as of 2026-06-05 risks sharp re-rating. Severity: high
  • Stock shows extreme sensitivity to AI headlines, e.g. -24% single-day drop on 2026-02-12 despite profit beat. Severity: medium
  • Revenue concentration with ~90% from North America as of FY2025 exposes single-market dependency. Severity: medium
  • Small workforce of ~132 employees as of 2026 relative to market cap creates key-person and execution risk. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
SectracontestingFrequently competes head-to-head with Visage for enterprise imaging deals, ongoing through 2025-2026
GE HealthCarelosing toLegacy Centricity PACS vendor repeatedly cited as losing enterprise deals to Visage 7 through 2025-2026
Aidocgaining on31+ FDA clearances, 2,000 hospitals, $150M Series E raised April 2026, total funding over $500M
Sirona Medicalgaining onCloud-native RadOS platform with agentic AI reporting positioned as full platform rival as of 2026-06
Questions people ask
Is Pro Medicus in financial trouble?
No signs of financial trouble appear in the evidence. Pro Medicus reported HY FY26 profit after tax of A$171.2 million, up 230.9% year over year (31 December 2025), and held cash and financial assets of A$221.8 million as of the same date, with no meaningful customer loss visible in the record.
Who are Pro Medicus's biggest competitors?
The legacy vendors GE Healthcare, Philips Healthcare, and Fujifilm compete but are described as losing ground due to older on-premise systems, according to the July 2026 assessment. Sectra AB is the more direct threat, a cloud-native rival actively contesting deals with Pro Medicus at top US hospitals; a watch-item tracks whether Sectra wins 2 to 3 marquee top-10 US academic medical center deals head-to-head by 31 July 2027.
Is Pro Medicus at risk from AI?
The AI threat is rated distant: no frontier AI lab has shipped an FDA-cleared PACS viewer as of the July 2026 assessment date. Investor fear that AI coding tools could erode its software edge is cited as a factor behind the stock's 50% decline, but no evidence in the record shows AI-driven customer loss or contract erosion so far.
Why has Pro Medicus stock fallen if the business looks strong?
The stock has fallen roughly 50% despite hospitals renewing and repricing contracts upward, reflecting investor fear that AI tools or larger rivals like Sectra could eventually catch up. The underlying numbers do not show that catch-up happening yet: HY FY26 revenue grew 28.4% year over year to A$124.8 million as of 31 December 2025, and forward-contracted revenue exceeded A$1.08 billion across 5 years as of 12 February 2026.
What gives Pro Medicus its competitive edge?
Its edge comes from deep integration into hospital imaging workflows and a cloud-native architecture that legacy rivals with on-premise stacks have struggled to match, per the July 2026 assessment. This is backed by repeated renewal wins and repricing power at large US academic medical centers, contracts renewed upward even as legacy vendors GE Healthcare, Philips Healthcare, and Fujifilm lose ground.
What should investors watch for with Pro Medicus in 2026?
Two dated checkpoints matter: by 31 August 2026, Pro Medicus is due to report its FY26 full-year underlying EBIT margin, following the 72.6% margin seen in HY FY26 (31 December 2025). A second watch-item, running to 31 July 2027, tracks whether Sectra AB manages to win 2 to 3 marquee top-10 US academic medical center deals head-to-head against Pro Medicus.
Timeline
  • 2026-06-24Binding HOA signed with Echo IQ for up to A$20M investment and US reseller rights to EchoSolv AI cardiac platform
  • 2026-06-05Morningstar rates Pro Medicus shares overvalued, fair value A$57 vs market ~A$150-160
  • 2026-06Allegheny Health Network renews $28M, 5-year Visage contract at higher fees than before
  • 2026-04Rival Aidoc raises $150M Series E led by Goldman Sachs, NVentures, total funding tops $500M
  • 2026-02-12Pro Medicus shares fall 24% in a single day despite a strong profit beat
  • 2026-01Aidoc receives FDA clearance for foundation-model body-CT triage covering 14 conditions
  • 2025-11-24AGM discloses FY26 YTD contracted sales of A$273 million minimum contract value
  • 2025-08-14FY2025 results: revenue A$213.0M (+31.9%), NPAT A$115.2M (+39.2%), 74.0% EBIT margin
  • 2025-07New $170M, 10-year contract announced for FY2026
Revision history
30 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Epic SystemsCochlear LimitedJMDC Inc
More in Medical technology and health companies →
Sources